melanotan ii mastery course
Unit 5 of 11

reported effects beyond tanning

appetite suppression, sexual arousal, and why multi-receptor activation is a liability

more than pigmentation

Because Melanotan II hits MC1R, MC3R, MC4R, and MC5R simultaneously, its reported effects extend well beyond skin darkening. Appetite suppression via MC4R, sexual arousal via MC3R/MC4R, and exocrine changes via MC5R are all downstream consequences of non-selective melanocortin agonism. These are not side effects -- they are the predictable result of the molecule's receptor profile.

effects by receptor dashboard

map each reported effect back to the melanocortin receptor subtype that mediates it.

effects by receptor dashboard

effects at a glance

key data points from clinical studies and community-reported use.

8 / 10
men with psychogenic ED who experienced erections on MT-II (Wessells 1998)
38 vs 3 min
tip rigidity >80% duration -- MT-II vs placebo (p=0.0045)
68 vs 19%
doses associated with increased sexual desire -- MT-II vs placebo (Wessells 2000)
2019
year PT-141 (Vyleesi) was FDA-approved -- derived from MT-II's accidental sexual effects
MT-II's effects are inextricably linked by its non-selective receptor profile. A user seeking a tan will also experience appetite changes, potential sexual effects, and nausea. There is no dosing strategy that can separate these effects -- the receptor affinities are too close together (0.67 nM to ~34 nM) for dose-dependent selectivity.

key terms

concepts central to understanding MT-II's multi-system effects.

AN anorexigenic appetite suppression
Appetite-suppressing. MT-II activates anorexigenic signaling through MC3R/MC4R in the arcuate and paraventricular nuclei of the hypothalamus, overriding the competing AgRP (hunger) signal.
CE central vs peripheral mechanism distinction
MT-II's sexual effects are centrally mediated (brain, MC4R), affecting both arousal and desire. PDE5 inhibitors like sildenafil act peripherally on blood vessel smooth muscle. This is why MT-II can initiate arousal without sexual stimulation.
AG AgRP endogenous antagonist
Agouti-related peptide. The endogenous MC4R antagonist that promotes feeding. MT-II overwhelms the AgRP signal with superpotent agonism, producing robust appetite suppression.
NS non-selectivity liability pharmacology
The fundamental pharmacological problem of MT-II. Effects at MC1R, MC3R, MC4R, and MC5R are inseparable because the binding affinities are all in the nanomolar range. The approved drugs solved this by engineering selectivity.

effect-to-receptor attribution

each reported effect traces back to a specific melanocortin receptor subtype.

skin darkening
MC1R on melanocytes. increased eumelanin synthesis via cAMP-MITF-tyrosinase cascade. the intended tanning effect.
appetite suppression
MC3R/MC4R in the hypothalamus. dose-dependent anorexigenic signaling. in rodents, body mass stays reduced even after food intake normalizes.
sexual arousal
MC4R in the CNS. centrally mediated -- affects both physiological response and psychological desire. led to bremelanotide development.
nausea
MC4R centrally mediated. most common acute side effect. dose-dependent, peaks 30-90 minutes post-injection, diminishes after first 3-5 days.